Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 103(2): 756-759, 2020 08.
Article in English | MEDLINE | ID: mdl-32394887

ABSTRACT

Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6 genetic polymorphisms that result in reduced or no enzyme activity. The distribution of CYP2D6 genotypes and predicted phenotypes in the Cambodian population is not well described. Surveys in other Asian countries have shown an approximate 50% prevalence of the reduced activity CYP2D6 allele *10, which could translate into increased risk of PQ radical cure failure and repeated relapses, making interruption of transmission and malaria elimination difficult to achieve. We determined CYP2D6 genotypes from 96 volunteers from Oddor Meanchey Province, Cambodia, an area endemic for Plasmodium vivax. We found a 54.2% frequency of the *10 allele, but in approximately half of our subjects, it was paired with a normal activity allele, either *1 or *2. The prevalence of *5, a null allele, was 9.4%. Overall predicted phenotype percentages were normal metabolizers, 46%; intermediate metabolizers, 52%; and poor metabolizers, 1%.


Subject(s)
Antimalarials/therapeutic use , Cytochrome P-450 CYP2D6/genetics , Malaria, Vivax/drug therapy , Primaquine/therapeutic use , Artemisinins/therapeutic use , Asian People/genetics , Cambodia , Drug Therapy, Combination , Endemic Diseases , Gene Frequency , Genotype , Humans , Pharmacogenomic Variants , Phenotype , Plasmodium vivax , Polymorphism, Genetic , Quinolines/therapeutic use , Recurrence , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...